PNA5 for VCID and Alzheimer's Dementias: A first-in-human safety study

Who could benefit from this research

What this research studies

This trial tests a new treatment called PNA5 in adults 21 and older who have VCID or Alzheimer’s-related dementias. It focuses on safety and tolerability in the initial phase, after completing animals and lab work and obtaining IND clearance. Participants would receive PNA5 or a placebo in a controlled setting to monitor safety signals, dosing, and preliminary effects on brain function. If safety looks good, findings will guide future studies to determine effectiveness and optimal dosing.

Why it matters

Where this research is happening

• University of Arizona
  Tucson, United States Active

Researchers

• Principal investigator: Hay, Meredith — University of Arizona
• Study coordinator: Hay, Meredith

Related research

Other NIH-funded projects on the same topics.

• Global picture of dementia risk and memory loss across the world

  A large international effort gathers data from many studies to understand how dementia and memory problems develop around the world, using shared information to reveal patterns and risk factors.

  NIH research University of New South Wales · Sydney, Australia · NIH-11603263

• Global picture of dementia and Alzheimer’s risk across populations

  A large international effort gathers health data from many cohorts to understand what increases or lowers the risk of dementia and Alzheimer's disease around the world.

  NIH research University of New South Wales · Sydney, Australia · NIH-11417899

• Global patterns of cognitive impairment and Alzheimer's dementia

  Bringing together memory-study data from around the world to find lifestyle and environmental factors people can change to lower the risk of Alzheimer's and related dementias.

  NIH research University of New South Wales · Sydney, Australia · NIH-11416183

• A brain-boosting peptide to help people at risk of vascular dementia and Alzheimer’s disease

  A new drug-like peptide (PNA5) is being studied to reduce brain inflammation and improve blood flow in people at risk for vascular dementia and Alzheimer's-related dementia.

  NIH research University of Arizona · Tucson, United States · NIH-11396379

• Scale-up of a peptide therapy to help brain blood flow and inflammation in people at risk for Alzheimer’s-related dementias

  A small US-based project will scale up manufacturing of a new peptide medicine (PNA5) intended to help people at risk for Alzheimer’s-related dementia and vascular dementia by improving brain blood flow and reducing inflammation.

  NIH research Proneurogen, INC. · Tucson, United States · NIH-11307341

• Vision and memory in people with end‑stage kidney disease (VIS‑HD)

  This project will see whether treating and understanding vision problems can help protect thinking and lower dementia risk for adults with end‑stage kidney disease.

  NIH research New York University School of Medicine · New York, United States · NIH-11247531

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.